Wells Fargo & Company MN lifted its stake in shares of Exactech, Inc. (NASDAQ:EXAC) by 14.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,907 shares of the medical equipment provider’s stock after acquiring an additional 9,566 shares during the quarter. Wells Fargo & Company MN owned 0.53% of Exactech worth $2,534,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. TIAA CREF Investment Management LLC increased its position in shares of Exactech by 11.1% during the second quarter. TIAA CREF Investment Management LLC now owns 34,438 shares of the medical equipment provider’s stock worth $1,026,000 after acquiring an additional 3,444 shares during the period. OxFORD Asset Management LLP increased its position in shares of Exactech by 17.8% during the second quarter. OxFORD Asset Management LLP now owns 59,972 shares of the medical equipment provider’s stock worth $1,787,000 after acquiring an additional 9,082 shares during the period. Northern Trust Corp increased its holdings in Exactech by 5.3% in the second quarter. Northern Trust Corp now owns 149,395 shares of the medical equipment provider’s stock valued at $4,452,000 after buying an additional 7,584 shares during the last quarter. Prudential Financial Inc. purchased a new position in Exactech in the second quarter valued at $359,000. Finally, Macquarie Group Ltd. purchased a new position in Exactech in the third quarter valued at $574,000. 58.88% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts recently commented on EXAC shares. Robert W. Baird set a $34.00 target price on Exactech and gave the company a “buy” rating in a report on Sunday, October 15th. Sidoti lowered Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Gabelli lowered Exactech from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Zacks Investment Research lowered Exactech from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Finally, ValuEngine lowered Exactech from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $49.00.
Exactech, Inc. (NASDAQ EXAC) traded down $0.38 during trading hours on Monday, reaching $49.67. The company had a trading volume of 135,606 shares, compared to its average volume of 105,367. The stock has a market capitalization of $719.03, a price-to-earnings ratio of 4,940.00, a PEG ratio of 3.70 and a beta of 0.90. Exactech, Inc. has a 52-week low of $23.75 and a 52-week high of $50.95. The company has a quick ratio of 2.09, a current ratio of 4.08 and a debt-to-equity ratio of 0.06.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/05/wells-fargo-company-mn-purchases-9566-shares-of-exactech-inc-exac.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.